The altered proteins were mapped into a core network, indicating that the anti-obesity effect of the peptide LLVVYPWTQR was mediated by regulating key proteins involved in two major regulatory pathways: the AMPK signalling pathway (SREBP-1c, PPARγ, and AMPKα) and a pathway associated with NAFLD (C/EBPα, SREBP-1c, and AMPKα) [56]. Here, SREBF1 is linked to metabolic dysfunction-associated steatotic liver disease.